Filing Details

Accession Number:
0001562180-24-001226
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-09 17:42:31
Reporting Period:
2024-02-07
Accepted Time:
2024-02-09 17:42:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1710072 Edgewise Therapeutics Inc. EWTX Pharmaceutical Preparations (2834) 821725586
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1853109 Behrad Derakhshan C/O Edgewise Therapeutics, Inc.
1715 38Th Street
Boulder CO 80301
Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-07 600 $1.93 7,620 No 4 M Direct
Common Stock Disposition 2024-02-07 600 $20.00 7,020 No 4 S Direct
Common Stock Acquisiton 2024-02-08 4,600 $1.93 11,620 No 4 M Direct
Common Stock Disposition 2024-02-08 4,600 $20.01 7,020 No 4 S Direct
Common Stock Acquisiton 2024-02-09 4,800 $1.93 11,820 No 4 M Direct
Common Stock Disposition 2024-02-09 4,800 $20.04 7,020 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-02-07 600 $0.00 600 $1.93
Common Stock Stock Option (Right to Buy) Disposition 2024-02-08 4,600 $0.00 4,600 $1.93
Common Stock Stock Option (Right to Buy) Disposition 2024-02-09 4,800 $0.00 4,800 $1.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
154,417 2030-12-15 No 4 M Direct
149,817 2030-12-15 No 4 M Direct
145,017 2030-12-15 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023.
  2. Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.